Company: SRPT
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001193125-25-269436
Chunk: 1

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
     300

     47,400

     Other non-current liabilities

     1,404

     1,750

     Total liabilities

     2,173,317

     2,435,431

     Commitments and contingencies (Note 18)

     Stockholders’ equity:

     Preferred stock, $0.0001 par value, 3,333,333 shares authorized; none issued and   outstanding

     —

     —

     Common stock, $0.0001 par value, 198,000,000 shares authorized; 105,418,987 and    104,768,111 issued and outstanding, respectively, at September 30, 2025 and 96,900,496    issued and outstanding at December 31, 2024

     11

     10

     Treasury stock, at cost, 650,876 and 0 shares at September 30, 2025 and    December 31, 2024, respectively

     (25,263
     )

     —

     Additional paid-in capital

     5,986,689

     5,738,924

     Accumulated other comprehensive income (loss), net of tax

     220

     (218
     )

     Accumulated deficit

     (4,641,537
     )

     (4,210,974
     )

     Total stockholders’ equity

     1,320,120

     1,527,742

     Total liabilities and stockholders’ equity
      
     $
     3,493,437

     $
     3,963,173

See accompanying notes to unaudited condensed consolidated financial statements.